(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Vertex forecasts upbeat 2025 revenue on ... 2025 UK health system to offer cutting-edge gene therapy for sickle cell disease Britain's National Health Service (NHS) will provide a cutting-edge ...

Vertex and CRISPR ... NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for sickle cell disease.

Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.

Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Illinois also submitted a letter of intent to participate in a new Cell and Gene Therapy (CGT) Access Model that the federal Centers for Medicare & Medicaid Services (CMS) Innovation Center is ...

Vertex Pharmaceuticals continues to see patients with sickle cell disease start the process to receive its Casgevy therapy, said Chief Operating Officer Stuart Arbuckle. He said the treatment ...

Vertex Pharmaceuticals is ranked among the best biotech stocks to buy, with 13 billionaires backing the company. Despite ...

Vertex Pharmaceuticals Incorporated ... The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.